Plasmacytoids dendritic cells are a therapeutic target in anticancer immunity

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 2, 2012, Pages 407-414

  Palma, Giuseppe ^a,d   De Laurenzi, Vincenzo ^b,e   De Marco, Margot ^c,e   Barbieri, Antonio ^a   Petrillo, Antonella ^a   Turco, Maria Caterina ^c,e   Arra, Claudio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e BIOUNIVERSA Srl   (Italy)

Author keywords

Cancer; Clinical trial; Immunology; Plasmacytoid dendritic cells

Indexed keywords

AGATOLIMOD; ALPHA2B INTERFERON; BONE MARROW STROMAL CELL ANTIGEN 2; CELL ANTIGEN; DENDRITIC CELL VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN LIKE TRANSCRIPT 7; INTERFERON; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

CANCER CONTROL; CANCER IMMUNOLOGY; CANCER THERAPY; CELL ACTIVATION; CELL FUNCTION; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; DRUG MEGADOSE; HUMAN; IMMUNOMODULATION; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; MYALGIA; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; NEOPLASMS; PHENOTYPE; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84864409767     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.04.007     Document Type: Review

References (93)

1. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
2. Liu Y.J. IPC: professional type 1 interferon producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005, 23:275-306.
3. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
4. Grouard G., Rissoan M.C., Filgueira L., Durand I., Banchereau J., Liu Y.J. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. 1997, 185:1101-1111.
5. Dzionek A., Sohma Y., Nagafune J., Cella M., Colonna M., Facchetti F., Günther G., Johnston I., Lanzavecchia A., Nagasaka T., Okada T., Vermi W., Winkels G., Yamamoto T., Zysk M., Yamaguchi Y., Schmitz J. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J. Exp. Med. 2001, 194:1823-1834.
6. Cao W., Rosen D.B., Ito T., Bover L., Bao M., Watanabe G., Yao Z., Zhang L., Lanier L.L., Liu Y.J. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J. Exp. Med. 2006, 203:1399-1405.
7. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., Liu Y.J. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194:863-869.
8. Jarrossay D., Napolitani G., Colonna M., Sallusto F., Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31:3388-3393.
9. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., Antonenko S., Liu Y.J. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
10. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 1999, 5:919-923.
11. Gilliet M., Cao W., Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008, 8:594-606.
12. Randolph G.J., Ochando J., Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 2008, 26:293-316.
13. Kohrgruber N., Groger M., Meraner P., Kriehuber E., Petzelbauer P., Brandt S., Stingl G., Rot A., Maurer D. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J. Immunol. 2004, 173:6592-6602.
14. Grouard G., Rissoan M.C., Filgueira L., Durand I., Banchereau J., Liu Y.J. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. 1997, 185:1101-1111.
15. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., Liu Y.J. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999, 283:1183-1186. (see comment).
16. Matsui T., Connolly J.E., Michnevitz M., Chaussabel D., Yu C.I., Glaser C., Tindle S., Pypaert M., Freitas H., Piqueras B., Banchereau J., Palucka A.K. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J. Immunol. 2009, 182:6815-6823.
17. Rissoan M.C., Duhen T., Bridon J.M., Bendriss-Vermare N., Péronne C., de Saint Vis B., Brière F., Bates E.E. Subtractive hybridization reveals the expression of immunoglobulin like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 2002, 100:3295-3303.
18. Blomberg S., Eloranta M.L., Magnusson M., Alm G.V., Ronnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum. 2003, 48:2524-2532.
19. Cao W., Bover L. Signaling and Ligand interaction of ILT7: receptor-mediated regulatory mechanism for plasmacytoid dendritic cell. Immunol. Rev. 2010, 234:163-176.
20. Pulendran B., Smith J.L., Caspary G., Brasel K., Pettit D., Maraskovsky E., Maliszewski C.R. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1036-1041.
21. Maraskovsky E., Brasel K., Teepe M., Lyman S.D., Shortman K., McKenna H.J. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 1996, 184:1953-1962.
22. Pulendran B., Lingappa J., Kennedy M.K., Smith J., Teepe M., Rudensky A., Maliszewski C.R., Maraskovsky E. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice. J. Immunol. 1997, 159:2222-2231.
23. Maraskovsky E., Daro E., Roux E., Teepe M., Maliszewski C.R., Hoek J., Caron D., Lebsack M.E., McKenna H.J. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000, 96:878-884.
24. Pulendran B., Banchereau J., Burkeholder S., Kraus E., Guinet E., Chalouni C., Caron D., Maliszewski C., Davoust J., Fay J., Palucka K. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 2000, 165:566-572.
25. Shurin M.R., Pandharipande P.P., Zorina T.D., Haluszczak C., Subbotin V.M., Hunter O., Brumfield A., Storkus W.J., Maraskovsky E., Lotze M.T. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell. Immunol. 1997, 179:174-184.
26. Brasel K., De Smedt T., Smith J.L., Maliszewski C.R. Generation of murine dendritic cells from flt3-ligandsupplemented bone marrow cultures. Blood 2000, 96:3029-3039.
27. Gilliet M., Boonstra A., Paturel C., Antonenko S., Xu X.L., Trinchieri G., O'Garra A., Liu Y.J. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 2002, 195:953-958.
28. Blom B., Ho S., Antonenko S., Liu Y.J. Generation of interferon α-producing predendritic cell (pre-DC)2 from human CD34+ hematopoietic stem cells. J. Exp. Med. 2000, 192:1785-1796.
29. Penna G., Sozzani S., Adorini L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J. Immunol. 2001, 167:1862-1866.
30. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T., Wei S., Krzysiek R., Durand-Gasselin I., Gordon A., Pustilnik T., Curiel D.T., Galanaud P., Capron F., Emilie D., Curiel T.J. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 2001, 7:1339-1346.
31. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
32. Cervantes-Barragan L., Lewis K.L., Firner S., Thiel V., Hugues S., Reith W., Ludewig B., Reizis B. Plasmacytoid dendritic cells control T-cell response to chronic viral infection. Proc. Natl. Acad. Sci. U. S. A. Feb 21 2012, 109(8):3012-3017. (Epub 2012 Feb 6).
33. Dental C., Florentin J., Aouar B., Gondois-Rey F., Durantel D., Baumert T.F., Nunes J.A., Olive D., Hirsch I., Stranska R. Hepatitis C virus fails to activate NF-κB signaling in plasmacytoid dendritic cells. J. Virol. Jan 2012, 86(2):1090-1096. (Epub 2011 Nov 16).
34. Barchet W., Cella M., Odermatt B., Asselin-Paturel C., Colonna M., Kalinke U. Virus induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo. J. Exp. Med. 2002, 195:507-516.
35. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switch-dendritic cells. Blood 2002, 100:3295-3303.
36. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.
37. Poeck H., Wagner M., Battiany J., Rothenfusser S., Wellisch D., Hornung V., Jahrsdorfer B., Giese T., Endres S., Hartmann G. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 2004, 103:3058-3064.
38. Penna G., Vulcano M., Roncari A., Facchetti F., Sozzani S., Adorini L. Cutting edge: differential chemokine production by myeloid and plasmacytoid dendritic cells. J. Immunol. 2002, 169:6673-6676.
39. Krug A., Uppaluri R., Facchetti F., Dorner B.G., Sheehan K.C., Schreiber R.D., Cella M., Colonna M. IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12 and secrete inflammatory chemokines upon activation. J. Immunol. 2002, 169:6079-6083.
40. Vanbervliet B., Bendriss-Vermare N., Massacrier C., Homey B., de Bouteiller O., Brière F., Trinchieri G., Caux C. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1) / CXCL12. J. Exp. Med. 2003, 198:823-830.
41. Kadowaki N., Ho S., Antonenko S., Malefyt R.W., Kastelein R.A., Bazan F., Liu Y.J. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J. Exp. Med. 2001, 194:863-870.
42. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdörfer B., Giese T., Endres S., Hartmann G. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 2002, 168:4531-4537.
43. Jarrossay D., Napolitani G., Colonna M., Sallusto F., Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31:3388-3393.
44. Lund J.M., Alexopoulou L., Sato A., Karow M., Adams N.C., Gale N.W., Iwasaki A., Flavell R.A. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:5598-5603.
45. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., Bauer S. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
46. Diebold S.S., Kaisho T., Hemmi H., Akira S., Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004, 303:1529-1531.
47. Bauer S., Kirschning C.J., Häcker H., Redecke V., Hausmann S., Akira S., Wagner H., Lipford G.B. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:9237-9242.
48. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
49. Haas T., Metzger J., Schmitz F., Heit A., Müller T., Latz E., Wagner H. The DNA sugar backbone 2'deoxyribose determines Toll-like receptor 9 activation. Immunity 2008, 28:315-323.
50. Jarrossay D., Napolitani G., Colonna M., Sallusto F., Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31:3388-3393.
51. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol. 2004, 25:381-386.
52. Park B., Brinkmann M.M., Spooner E., Lee C.C., Kim Y.M., Ploegh H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat. Immunol. 2008, 9:1407-1414.
53. Ewald S.E., Lee B.L., Lau L., Wickliffe K.E., Shi G.P., Chapman H.A., Barton G.M. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 2008, 456:658-662.
54. Mandl J.N., Akondy R., Lawson B., Kozyr N., Staprans S.I., Ahmed R., Feinberg M.B. Distinctive TLR7 signaling, type I IFN production, and attenuated innate and adaptive immune responses to yellow fever virus in a primate reservoir host. J. Immunol. 2011, 186(11):6406-6416. [Electronic publication ahead of print 2011 Apr 22].
55. Kumar H., Kawai T., Akira S. Pathogen recognition in the innate immune response. J. Biochem. 2009, 420:1-16.
56. Kawai T., Sato S., Ishii K.J., Coban C., Hemmi H., Yamamoto M., Terai K., Matsuda M., Inoue J., Uematsu S., Takeuchi O., Akira S. Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 2004, 5:1061-1068.
57. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
58. Honda K., Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 2006, 6:644-658.
59. Tel J., Beenhakker N., Koopman G., Hart B., Mudde G.C., de Vries I. Targeted delivery of CpG ODN to CD32 on human and monkey plasmacytoid dendritic cells augments IFNα secretion. J. Immunobiol. Jan 24 2012.
60. Krug A., Veeraswamy R., Pekosz A., Kanagawa O., Unanue E.R., Colonna M., et al. Interferon-producing cells fail to induce proliferation of naïve T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J. Exp. Med. 2003, 197:899-906.
61. Naranjo-Gomez M., Fernandez M.A., Bofill M., Singh R., Navarrete C.V., Pujol-Borrell R., et al. Primary alloproliferative TH1 response induced by immature plasmacytoid dendritic cells in collaboration with myeloid DCs. Am. J. Transplant. 2005, 5:2838-2848.
62. Kasturi S.P., Pulendran B. Cross-presentation: avoiding trafficking chaos?. Nat. Immunol. 2008, 9:461-463.
63. Colonna M., Cella M. Cross-presentation: plasmacytoid dendritic cells are in the business. Immunity 2007, 27:419-421.
64. Nierkens S., den Brok M.H., Garcia Z., Togher S., Wagenaars J., Wassink M., Boon L., Ruers T.J., Figdor C.G., Schoenberger S.P., Adema G.J., Janssen E.M. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res. Oct 15 2011, 71(20):6428-6437.
65. Hartmann E., Wollenberg B., Rothenfusser S., Wagner M., Wellisch D., Mack B., Giese T., Gires O., Endres S., Hartmann G. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003, 63:6478-6487.
66. Perrot I., Blanchard D., Freymond N., Isaac S., Guibert B., Pachéco Y., Lebecque S. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J. Immunol. 2007, 178:2763-2769.
67. Sorrentino R., Morello S., Forte G., Montinaro A., De Vita G., Luciano A., Palma G., Arra C., Maiolino P., Adcock I.M., Pinto A. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am. J. Respir. Crit. Care Med. 2011, 183:1369-1379.
68. Umemoto E., Otani K., Ikeno T., Verjan Garcia N., Hayasaka H., Bai Z., Jang M.H., Tanaka T., Nagasawa T., Ueda K., Miyasaka M. Constitutive Plasmacytoid Dendritic Cell Migration to the Splenic White Pulp Is Cooperatively Regulated by CCR7- and CXCR4-Mediated Signaling. J. Immunol. 2012, 189(1):191-199. [Electronic publication ahead of print 2012 May 25].
69. + regulatory T cells in human ovarian carcinoma. Cancer Res. 2005, 65:5020-5026.
70. Sharma M.D., Baban B., Chandler P., Hou D.Y., Singh N., Yagita H., Azuma M., Blazar B.R., Mellor A.L., Munn D.H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 2007, 117:2570-2582.
71. Aspord C., Charles J., Leccia M.T., Laurin D., Richard M.J., Chaperot L., Plumas J. A novel cancer vaccine strategy based on HLA-A0201 matched allogeneic plasmacytoid dendritic cells. PLoS One 2010, 5:e10458. 10.1371/journal.pone.0010458.
72. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
73. Hofmann M.A., Kors C., Audring H., Walden P., Sterry W., Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother. 2008, 31:520-527.
74. Ito T., Amakawa R., Kaisho T., Hemmi H., Tajima K., Uehira K., Ozaki Y., Tomizawa H., Akira S., Fukuhara S. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J. Exp. Med. 2002, 195:1507-1512.
75. Miller R.L., Gerster J.F., Owens M.L., Slade H.B., Tomai M.A. Imiquimod applied topically: a novel immune response modifier and newclass of drug. Int. J. Immunopharmacol. 1999, 21:1-14.
76. Dummer R., Urosevic M., Kempf W., Hoek K., Hafner J., Burg G. Imiquimod in basal cell carcinoma: how does it work?. Br. J. Dermatol. 2003, 149:57-58.
77. Wolf I.H., Smolle J., Binder B., Cerroni L., Richtig E., Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch. Dermatol. 2003, 139:273-276.
78. Steinmann A., Funk J.O., Schuler G., von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J. Am. Acad. Dermatol. 2000, 43:555-556. (see comment).
79. Drobits B., Holcmann M., Amberg N., Swiecki M., Grundtner R., Hammer M., Colonna M., Sibilia M.J. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. Feb 1 2012, 122(2):575-585. (Epub 2012 Jan 17).
80. Correale P., Botta C., Cusi M.G., Del Vecchio M.T., De Santi M.M., Gori Savellini G., Bestoso E., Apollinari S., Mannucci S., Marra M., Abbruzzese A., Aquino A., Turriziani M., Bonmassar L., Caraglia M., Tagliaferri P. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int. J. Cancer Apr 1 2012, 130(7):1577-1589. (Epub 2011 Aug 16).
81. Correale P., Cusi M.G., Del Vecchio M.T., Aquino A., Prete S.P., Tsang K.Y., Micheli L., Nencini C., La Placa M., Montagnani F., Terrosi C., Caraglia M., Formica V., Giorgi G., Bonmassar E., Francini G. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J. Immunol. Jul 15 2005, 175(2):820-828.
82. Caraglia M., Marra M., Tagliaferri P., Lamberts S.W., Zappavigna S., Misso G., Cavagnini F., Facchini G., Abbruzzese A., Hofland L.J., Vitale G. Emerging strategies to strengthen the anti-tumor activity of type I interferons: overcoming survival pathways. Curr. Cancer Drug Targets Aug 2009, 9(5):690-704. (Epub 2009 Aug 1. Review).
83. Caraglia M., Vitale G., Marra M., Budillon A., Tagliaferri P., Abbruzzese A. Alpha-interferon and its effects on signalling pathways within cells. Curr. Protein Pept. Sci. Dec 2004, 5(6):475-485. (Review).
84. Caraglia M., Marra M., Pelaia G., Maselli R., Caputi M., Marsico S.A., Abbruzzese A. Alpha-interferon and its effects on signal transduction pathways. J. Cell. Physiol. Feb 2005, 202(2):323-335. (Review).
85. Chaperot L., Bendriss N., Manches O., Gressin R., Maynadie M., Trimoreau F., Orfeuvre H., Corront B., Feuillard J., Sotto J.J., Bensa J.C., Brière F., Plumas J., Jacob M.C. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001, 97:3210-3217.
86. Chaperot L., Perrot I., Jacob M.C., Blanchard D., Salaun V., Deneys V., Lebecque S., Brière F., Bensa J.C., Plumas J. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur. J. Immunol. 2004, 34:418-426.
87. Marafioti T., Paterson J.C., Ballabio E., Reichard K.K., Tedoldi S., Hollowood K., Dictor M., Hansmann M.L., Pileri S.A., Dyer M.J., Sozzani S., Dikic I., Shaw A.S., Petrella T., Stein H., Isaacson P.G., Facchetti F., Mason D.Y. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood 2008, 111:3778-3792.
88. Chin D., Boyle G.M., Theile D.R., Parsons P.G., Coman W.B. Molecular introduction to head and neck cancer (HNSCC) carcinogenesis. Br. J. Plast. Surg. 2004, 57:595-602.
89. Bong A.B., Bonnekoh B., Franke I., Schon M.P., Ulrich J., Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 2002, 205:135-138.
90. Palamara F., Meindl S., Holcmann M., Luhrs P., Stingl G., Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J. Immunol. 2004, 173:3051-3061.
91. Wolf I.H., Kodama K., Cerroni L., Kerl H. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am. J. Dermatopathol. 2007, 29:237-241.
92. Naing A., Reuben J.M., Camacho L.H., Gao H., Lee B.N., Cohen E.N., Verschraegen C., Stephen S., Aaron J., Hong D., Wheler J., Kurzrock R. Phase I dose escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon alpha for patients with solid tumors. J. Cancer 2011, 10:81-89.
93. Zent C.S., Smith B.J., Ballas Z.K., Wooldridge J.E., Link B.K., Call T.G., Shanafelt T.D., Bowen D.A., Kay N.E., Witzig T.E., Weiner G.J. Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk. Lymphoma Feb 2012, 53(2):211-217. (Epub 2011 Sep 19).